3SBio Stock

3SBio EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3SBio (1530.HK) as of Aug 15, 2026 is 12.26 B CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 3.04 B CNY — a change of 303.76% (higher).

EBITDA

12.26 BCNY

YoY

303.76%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3SBio is 2026 12.26 B CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3SBio was 2025 3.04 B CNY. It decreases by 303.76% higher compared to the previous year.
Access this data via the Eulerpool API

3SBio Stock analysis

What does 3SBio do? 3SBio Inc. is a biopharmaceutical company from China that specializes in the research, development, manufacturing, and marketing of biological products. It was founded in 1993 in Shenyang, a city in northeast China, and its headquarters are now in Beijing. 3SBio's business model is based on the development and manufacturing of biopharmaceuticals that are used to treat cancer, autoimmune diseases, and other serious illnesses. The company focuses on biological medicines such as proteins, antibodies, and peptides that are produced using genetic technology. 3SBio operates a wide range of business sectors, including the manufacturing and sale of biopharmaceutical products, the manufacturing and sale of generics and biosimilar products, and research and development in the biotechnology field. The company also has several subsidiaries and joint ventures, including 3SBio International Holding, Sunshine Guojian Pharmaceutical, and Target Pharma. A well-known product of 3SBio is erythropoietin (EPO), which is used in the treatment of anemia. The company also has a portfolio of other biopharmaceutical products that are used to treat cancer, autoimmune diseases, and other serious illnesses. The history of 3SBio goes back to 1993 when it was founded as Shenyang Sunshine Pharmaceutical. In 2001, the company was renamed "Shenyang Sunshine Pharmaceutical Co. Ltd. 3S Bio" and focused on biological therapy. In 2007, the company successfully listed on the Hong Kong Stock Exchange and received the name 3SBio. In 2013, the company was privatized and acquired by a consortium of Chinese investment companies. 3SBio has a strong presence in China and is also expanding into international markets. The company has distribution partnerships in Asia, Europe, and North America, and plans to enter more markets. Overall, 3SBio is a leading company in China in the field of biopharmaceuticals that focuses on the treatment of serious illnesses. The company aims to be a leader in research and development, as well as in the manufacturing and sale of innovative products, and to expand its presence in global markets. 3SBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 3SBio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3SBio is 12.26 B CNY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of 3SBio changed from 3.04 B CNY to 12.26 B CNY, representing a 303.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) 3SBio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s 3SBio historically and in real time.

Access this data via the Eulerpool API

Income Statement — 3SBio

All Key Metrics — 3SBio